New Therapies to Correct the Cystic Fibrosis Basic Defect.

Area of Science:

• Genetics and Molecular Biology
• Pulmonology
• Pharmacology

Background:

• Rare diseases, including cystic fibrosis (CF), present significant challenges in diagnosis and treatment.
• Historically, CF therapies focused on managing symptoms rather than addressing the root cause.
• The identification of the cystic fibrosis transmembrane conductance regulator (CFTR) gene revolutionized understanding of CF's basic defect.

Purpose of the Study:

• To review current knowledge of cystic fibrosis genetics.
• To summarize therapies aimed at restoring CFTR protein function.
• To highlight the role of CFTR modulators and gene therapy in CF treatment.

Main Methods:

• Literature review of CF genetics and therapeutic advancements.
• Analysis of research on CFTR protein function and dysfunction.
• Synthesis of data on current and emerging CFTR-targeting therapies.

Main Results:

• CFTR modulators represent a significant advancement, correcting, potentiating, stabilizing, or amplifying CFTR function.
• Gene therapy research is progressing, aiming for broader efficacy in the CF community.
• Targeted therapies are shifting focus from symptom management to addressing the genetic basis of CF.

Conclusions:

• CFTR modulators have transformed outcomes for many CF patients.
• Ongoing research into gene therapy and other targeted approaches promises further improvements.
• A deeper understanding of CF genetics underpins the development of these innovative treatments.